Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Astellas Pharma
Woman and Man
Between 18 years
and 99 years
Astellas Pharma
Update Il y a 4 ans
Astellas Pharma 155-CL-031 : Essai de phase 2 évaluant l'efficacité et la tolérance d'un inhibiteur de la survivine (YM155) associé à du rituximab, chez des patients ayant un lymphome non-hodgkinien à cellules B CD20+, en rechute. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase II, multicenter, open-label study of YM155 plus rituximab In previously treated subjects with CD20-positive B cell non-Hodgkin's lymphoma who are ineligible for or have previously received an ...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Astellas Pharma Global Development, Inc
Update Il y a 4 ans
Study comparing Tivozanib in combination with mFOLFOX6 against Bevacizumab in combination with mFOLFOX6 in patients with bowel cancer
To compare progression-free survival (PFS) between tivozanib in combination with mFOLFOX6 with bevacizumab in combination with mFOLFOX6 based on investigator radiological tumor assessment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years and 75 years
Astellas Pharma
Update Il y a 4 ans
Étude 2215-CL-0201 : étude de phase 2-3 randomisée visant à comparer l’efficacité du giltéritinib (ASP2215)en monothérapie à l’ASP2215 en association à l’azacitidine et à l’azacitidine en monothérapie chez des patients ayant une leucémie myéloïde aiguë nouvellement diagnostiquée mutée pour le FTL3 non éligibles pour une chimiothérapie d’induction intensive.
La leucémie myéloïde aiguë résulte des mutations acquises dans l’ADN de cellule de la moelle osseuse en développement. Cette cellule devient leucémique et se multiplie de façon incontrôlable, donnant ...
Country
France
organs
Leucémies aiguës
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Astellas Pharma Global Development, Inc (APGD)
Update Il y a 4 ans
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
The objective of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects who are Methotrexate-Inadequate Responders (MTX-IR).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
INVESTIGATING NEW ONSET DIABETES MELLITUS IN KIDNEY TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT CORTICOSTEROIDS – A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY
To compare the two treatment arms with regard to incidence of new onset diabetes Mellitus as per the American Diabetic Association criteria at any point up to 24 weeks after kidney transplantation. Ar...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Astellas Pharma GmbH
Update Il y a 4 ans
A MULTICENTRE, 1:1 RANDOMISED, DOUBLE BLIND, TWO ARM PARALLEL GROUP STUDY TO EVALUATE AND COMPARE THE EFFICACY AND SAFETY OF MODIFIED RELEASE TACROLIMUS FK506E (MR4) VERSUS TACROLIMUS FK506 IN COMBINATION WITH MMF (CELLCEPT®) AND STEROIDS IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION
The study aims to evaluate and to compare the efficacy and safety of a triple modified release tacrolimus FK506E (MR4) / MMF / steroid regimen with a triple standard tacrolimus FK506 / MMF / steroid r...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A study to assess the long-term efficacy and safety of two medicines, solifenacin succinate and mirabegron, taken together or separately, in patients with overactive bladder
To evaluate the safety and tolerability of long-term combination treatment of solifenacin (5 mg) with mirabegron (50 mg) compared to solifenacin and mirabegron monotherapy in subjects with overactive ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Europe Ltd
Update Il y a 4 ans
Randomized, Open label, Non-inferiority Study of Micafungin versus Standard Care for the Prevention of Invasive Fungal Disease in High Risk Liver Transplant Recipients
To demonstrate non-inferiority of micafungin at a dose of 100 mg/day versus ‘standard care’ for the prevention of Invasive Fungal Disease, defined according to the revised EORTC/MSG criteria, in ‘high...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Astellas Pharma Canada Inc
Update Il y a 4 ans
Comparison of tacrolimus and cyclosporin therapy in heart transplantation
To investigate changes in subcellular markers of growth, apoptosis, differentiation, survival, inflammation and oxidative stress, in relationship with cellular acute rejection, in de novo cardiac tran...
Country
None
organs
None
Specialty
None
More information
Man Max 99 years
Astellas Pharma Europe B.V
Update Il y a 4 ans
A randomized, double-blind, parallel group, placebo controlled, multi center dose ranging study of solifenacin succinate (3 mg, 6 mg and 9 mg) in combination with tamsulosin OCAS 0.4 mg compared with solifenacin succinate monotherapy (3 mg, 6 mg and 9 mg) and tamsulosin OCAS 0.4 mg monotherapy in males with lower urinary tract symptoms
To assess whether the combination of solifenacin succinate (3, 6, 9 mg) and tamsulosin OCAS 0.4 mg provides improved efficacy compared to tamsulosin OCAS 0.4 mg alone in males with LUTS associated wit...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next